Drug development for CNS disorders: strategies for balancing risk and reducing attrition

@article{Pangalos2007DrugDF,
  title={Drug development for CNS disorders: strategies for balancing risk and reducing attrition},
  author={Menelas N. Pangalos and Lee E. Schechter and Orest Hurko},
  journal={Nature Reviews Drug Discovery},
  year={2007},
  volume={6},
  pages={521-532}
}
Disorders of the central nervous system (CNS) are some of the most prevalent, devastating and yet poorly treated illnesses. The development of new therapies for CNS disorders such as Alzheimer's disease has the potential to provide patients with significant improvements in quality of life, as well as reduce the future economic burden on health-care systems. However, few truly innovative CNS drugs have been approved in recent years, suggesting that there is a considerable need for strategies to… CONTINUE READING